Social responsibility may be a key reason why researchers are still conducting trials for chloroquine as a Covid-19 treatment despite recent setbacks, says an analyst.

Last month, an international group of researchers began clinical trials to investigate whether the anti-malaria drug could prevent the novel coronavirus, or reduce its severity in front-line healthcare workers.

And this trial looks set to continue — even though the WHO (World Health Organisation) announced on May 25 it was temporarily dropping hydroxychloroquine from its global study of potential Covid-19 treatments due to safety concerns.

Read the full article here.